These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 9771846)

  • 41. Anti-glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients.
    Aguilera I; Alvarez-Marquez A; Gentil MA; Fernandez-Alonso J; Fijo J; Saez C; Wichmann I; Nuñez-Roldan A
    Nephrol Dial Transplant; 2008 Jul; 23(7):2393-8. PubMed ID: 18308775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients.
    Akalin E; Ames S; Sehgal V; Fotino M; Daly L; Murphy B; Bromberg JS
    Transplantation; 2003 Nov; 76(10):1444-7. PubMed ID: 14657683
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.
    Montgomery RA; Zachary AA; Racusen LC; Leffell MS; King KE; Burdick J; Maley WR; Ratner LE
    Transplantation; 2000 Sep; 70(6):887-95. PubMed ID: 11014642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. De novo production of donor-specific anti-HLA alloantibodies in early acute humoral renal allograft rejection.
    Spriewald BM; Hugo C
    Clin Transpl; 2006; ():469-72. PubMed ID: 18365405
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization.
    Ata P; Canbakan M; Kara M; Özel L; Ünal E; Titiz Mİ
    Transplant Proc; 2012; 44(6):1652-5. PubMed ID: 22841237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blood group Lewis alloantibodies cause antibody-mediated rejection in renal transplant recipients.
    Boratyńska M; Banasik M; Hałoń A; Patrzałek D; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2711-4. PubMed ID: 18021965
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abrogation of anti-HLA antibodies via proteasome inhibition.
    Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
    Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of allosensitized cardiac transplant candidates.
    Velez M; Johnson MR
    Transplant Rev (Orlando); 2009 Oct; 23(4):235-47. PubMed ID: 19778695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of high-dose human immune globulin in highly sensitized patients on the kidney transplant waiting list: one center's experience.
    Gozdowska J; Urbanowicz A; Perkowska-Ptasinska A; Michalska K; Chmura A; Szmidt J; Durlik M
    Transplant Proc; 2009 Oct; 41(8):2997-3001. PubMed ID: 19857660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progress in understanding humoral rejection in kidney transplantation: implications for patient management.
    Pascual MA; Crespo M; Tolkoff-Rubin N
    Nefrologia; 2001; 21(4):327-31. PubMed ID: 11816504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
    Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
    Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low median fluorescence intensity could be a nonsafety concept of immunologic risk evaluation in patients with shared molecular eplets in kidney transplantation.
    Bosch A; Llorente S; Diaz JA; Salgado G; López M; Boix F; López-Hernández R; González-Soriano MJ; Campillo JA; Moya-Quiles MR; Perez-Lopez N; Minguela A; Jimeno L; Alvarez-López MR; Muro M
    Hum Immunol; 2012 May; 73(5):522-5. PubMed ID: 22425738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The association of enhancement of renal allograft survival by donor-specific blood transfusion with host MHC-linked inhibition of IgG anti-donor class I alloantibody responses.
    Wasowska B; Baldwin WM; Howell DN; Sanfilippo F
    Transplantation; 1993 Sep; 56(3):672-80. PubMed ID: 7692630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody-mediated rejection.
    Akalin E; Watschinger B
    Semin Nephrol; 2007 Jul; 27(4):393-407. PubMed ID: 17616272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients.
    Yamada C; Ramon DS; Cascalho M; Sung RS; Leichtman AB; Samaniego M; Davenport RD
    Transfusion; 2015 Apr; 55(4):727-35; quiz 726. PubMed ID: 25385678
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HLA-specific alloantibodies and renal graft outcome.
    Sumitran-Holgersson S
    Nephrol Dial Transplant; 2001 May; 16(5):897-904. PubMed ID: 11328893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.